Acquisition momentum Forbius was acquired by Bristol Myers Squibb in August 2020, indicating a strong validation of its biotherapeutics platform and potential access to larger commercialization resources and pipelines.

Clinical-stage focus As a clinical-stage company with expertise in designing inhibitors for EGFR and TGF-β pathways, Forbius presents opportunities for collaboration on early-stage programs, co-development, or licensing of novel constructs targeting cancer and fibrotic diseases.

Targeted pathways Specialization in TGF-β and EGFR pathways offers a clear value proposition for BD discussions with partners pursuing fibrosis, oncology, or combination therapies where inhibitors of these validated pathways could fill unmet medical needs.

Funding and scale fit Current revenue and modest funding indicate a small but active organization with potential for partner-led programs, milestone-driven deals, or services that extend commercialization readiness without heavy internal scaling.

Awards and recognition Historical recognition such as the Best New Drug Developer award highlights credibility in the ADC and biotherapeutics space, which can be leveraged in outreach to potential collaborators seeking innovative biologics platforms.